Research Use Only. Not for human therapeutic use. All data cited from peer-reviewed preclinical literature.
The endocrine system — encompassing the hypothalamic-pituitary axis and its downstream endocrine glands (thyroid, adrenal cortex, gonads, pancreas, parathyroid, pineal) — is regulated by a hierarchy of feedback loops, peptide hormones, and signalling cascades that govern metabolism, stress response, reproduction, growth, and circadian biology. Peptide research compounds that modulate endocrine axes are among the most mechanistically rich tools available for preclinical research. This hub guide surveys the key peptides used in endocrine research, their primary hormonal axis interactions, mechanistic signatures, and relevant research models — serving as an orientation framework for researchers investigating hypothalamic-pituitary-target organ biology.
Growth Hormone Axis Peptides: Pituitary Somatotroph Research
The GH/IGF-1 axis is regulated by hypothalamic GHRH (stimulatory) and somatostatin (inhibitory) acting on pituitary somatotrophs, with GH-driven hepatic IGF-1 production providing the primary negative feedback. Multiple research peptides target this axis at different points.
CJC-1295 (GHRH analogue, DAC technology) extends GHRH half-life from 30 min to 6–8 days through albumin-binding, amplifying pulsatile GH secretion and sustained IGF-1 elevation. Research applications: somatopause reversal (aged rodent GH pulse deconvolution analysis), metabolic syndrome GH axis dysregulation (DIO model visceral adiposity, HOMA-IR, dyslipidaemia), and body composition (EchoMRI fat:lean ratio, caliper measurement). The GHRHR-Gs-cAMP-PKA-IP₃ somatotroph signal cascade is the primary research target.
Sermorelin (GHRH(1-29) truncated analogue) provides shorter-acting pulsatile GH stimulation — maintaining more physiological GH pulsatility than DAC-modified analogues. Research applications: pituitary reserve testing (stimulation test for GH deficiency — peak serum GH after sermorelin i.v. as pituitary secretory capacity index), GH axis ageing (somatopause animal models), and combined neuroendocrine-metabolic research.
Ipamorelin and GHRP-6 (GHS-R1a agonists) act on the ghrelin receptor (GHS-R1a) in pituitary and hypothalamus, releasing GH through a complementary mechanism to GHRH — suppressing somatostatin tone (through hypothalamic GHS-R1a) and directly stimulating somatotrophs (through pituitary GHS-R1a). Key mechanistic distinction: ipamorelin is highly selective for GHS-R1a with minimal cortisol/prolactin release; GHRP-6 shows broader receptor interactions. Research designs combining GHRH analogue + GHS (e.g., CJC-1295 + ipamorelin) achieve supra-additive GH release through the GHRH-GHS complementary mechanism — relevant to metabolic syndrome, ageing, and body composition research models.
Tesamorelin (GHRH(1-44) analogue with trans-3-hexenoic acid modification) has a specific clinical and preclinical research profile focused on HIV-associated lipodystrophy and MASH (metabolic-associated steatohepatitis). Research applications: visceral adiposity measurement (CT/MRI VAT area), hepatic steatosis (NAS histological score, MRI-PDFF fat fraction), and triglyceride-HDL dyslipidaemia reversal in GH axis dysregulation contexts.
Hypothalamic-Pituitary-Adrenal Axis Research Peptides
The HPA axis — CRH (paraventricular nucleus) → ACTH (anterior pituitary corticotrophs) → cortisol/corticosterone (adrenal cortex) — is the central stress-response endocrine system. Glucocorticoid receptor (GR) feedback on PVN CRH and pituitary ACTH provides negative regulation. Chronic HPA dysregulation (hyperactivation in chronic stress, depression, PTSD; hypoactivation in burnout and post-sepsis) produces metabolic, immune, and neurological consequences.
Selank is a synthetic analogue of the immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg) with documented HPA axis modulatory activity. In chronic stress and depression models (CMS, UCMS, forced swim), Selank attenuates HPA hyperactivation — reducing peak corticosterone, normalising GR NR3C1 nuclear translocation, and reducing FKBP5/FKBP51 (negative GR feedback regulator elevated in stress). Selank’s anxiolytic and anti-stress effects converge on HPA normalisation, making it a relevant tool for research investigating stress-HPA-immune crosstalk.
Semax (ACTH(4-10) synthetic analogue without glucocorticoid-stimulating activity of full ACTH) modulates HPA axis-related biology independently of adrenocortical stimulation. Semax lacks the Phe-7 residue critical for adrenocortical ACTH activity but retains cognitive and neuroprotective activity. Research applications: Semax as an ACTH-fragment tool to dissect melanocortin receptor-mediated CNS effects from glucocorticoid axis effects — particularly relevant for stress neuroscience research where separating ACTH melanocortin signalling from HPA-cortisol consequences is methodologically important.
DSIP (Delta Sleep-Inducing Peptide) modulates HPA axis through interactions with CRH neuronal circuits and cortisol rhythm synchronisation. DSIP reduces CRH mRNA in PVN during stress models and normalises 24-hour corticosterone patterns (radiotelemetry, serial blood sampling) in circadian disruption models. The DSIP-HPA-sleep axis research intersection is a productive niche for researchers studying stress-sleep bidirectional biology.
HPG Axis (Reproductive Endocrine) Research Peptides
The hypothalamic-pituitary-gonadal axis — GnRH (hypothalamic kisspeptin-driven) → LH/FSH (pituitary gonadotrophs) → sex steroids (gonads) — governs reproductive biology across the lifespan. Research peptides modulating this axis offer tools for fertility, puberty, menopause, and androgen research.
Kisspeptin-10 is the endogenous activator of GnRH neurons — the master reproductive endocrine switch. Kisspeptin-10 (the C-terminal decapeptide of kisspeptin-54) binds GPR54/Kiss1r on GnRH neurons, driving GnRH pulse release and consequent LH surge (pulsatile LH by frequent sampling RIA/ELISA). Research applications: HPG axis stimulation testing (functional hypothalamic amenorrhoea research — distinguishing hypothalamic from pituitary GnRH deficiency), puberty timing research (kisspeptin ARC-AVPV neuronal circuit maturation), and testosterone/oestradiol axis regulation in males and females. Kisspeptin-10 is the most upstream HPG axis research tool available.
Follistatin modulates FSH specifically by sequestering activin A/B — blocking their Smad2/3-mediated FSHβ transcription in pituitary gonadotrophs. Research applications: ovarian follicle selection biology, FSH-independent reproductive endocrine studies, and testicular Sertoli cell biology. Follistatin enables FSH axis research with receptor-level specificity not available from GnRH or kisspeptin approaches.
PT-141 (Bremelanotide) acts centrally through MC3R and MC4R in the PVN, MPOA, and VTA — engaging the melanocortin reproductive axis rather than classical HPG biology. Research applications: central arousal mechanisms (erectile dysfunction neuroscience — intracavernous pressure ICP recording with NOS/eNOS L-NAME dissection), female sexual dysfunction (BNST-MPOA circuit biology, oestrous cycle interaction), and MC4R-social/reproductive behaviour circuits. PT-141’s reproductive biology research is primarily neural rather than endocrine in the classical sense.
Pineal Gland and Circadian Endocrinology Research
Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide designed from the pineal gland extract epithalamin, with documented effects on melatonin biosynthesis and circadian biology. Epitalon upregulates AANAT (arylalkylamine N-acetyltransferase — the rate-limiting melatonin synthesis enzyme) through pinealocyte GnRH receptor binding and cAMP-PKA pathway activation, restoring age-associated melatonin decline. Research applications: circadian rhythm restoration in aged rodents (aMT6s urinary melatonin metabolite ELISA, circadian locomotor activity rhythm by running wheel or InfraMot telemetry), pineal gland telomerase activation (TERT expression in pinealocytes by IHC/western blot — TERT drives Ala-Glu-Asp-Gly responsive melatonin restoration), and melatonin-immune axis interactions in ageing and cancer biology.
Epitalon’s melatonin-restoration research intersects with adrenal and gonadal endocrine biology: melatonin suppresses cortisol (through SCN-mediated HPA circadian entrainment) and modulates GnRH pulsatility (seasonal reproductive biology). Research designs examining Epitalon through the melatonin → HPA → HPG multi-axis lens provide an integrated chronobiological endocrine perspective.
Metabolic Endocrine Research: Incretin Axis Peptides
The incretin endocrine axis — GIP (glucose-dependent insulinotropic polypeptide) from K-cells and GLP-1 (glucagon-like peptide-1) from L-cells of the intestinal mucosa — drives 50–70% of postprandial insulin secretion. GLP-1R and GIPR are expressed on pancreatic β-cells, and their activation drives glucose-stimulated insulin secretion (GSIS). Research peptides targeting this axis include Tirzepatide (dual GIP/GLP-1 agonist) and Retatrutide (triple GIP/GLP-1/glucagon agonist).
Tirzepatide research: GIP/GLP-1 receptor dual agonism produces complementary insulin secretion, weight reduction (hypothalamic satiety and gastric emptying delay), and hepatic steatosis improvement. Research applications include MASH (NAS histological scoring in STAM or fructose-fat-cholesterol diet models), pancreatic β-cell mass preservation (PDX1+/insulin+ islet IHC morphometry), and cardiovascular MACE risk reduction (atherosclerosis models in ApoE-KO+HFD mice).
Retatrutide adds glucagon receptor (GCGR) agonism to GIP/GLP-1 dual agonism — amplifying lipolysis (glucagon’s hepatic and adipose lipolytic effect) beyond GLP-1 alone. Research applications: extreme adiposity models, visceral fat mobilisation (CT/MRI VAT area, adipose tissue gene expression Fasn-Scd1-Hsl-Atgl), and hepatic glucose production modulation (PEPCK-G6Pase-FoxO1 nuclear exclusion in clamp studies). Retatrutide’s triple agonism provides a research tool to dissect individual GIP, GLP-1, and glucagon receptor contributions to metabolism through factorial receptor antagonist designs.
Thymic Endocrine Research: Thymosin Alpha-1
Thymosin Alpha-1 (Tα1) represents the thymic endocrine axis — the thymus’s hormonal role in T-cell education and immune regulation. Tα1 was originally isolated from thymosin fraction 5, a thymic extract containing multiple bioactive peptides. As an endocrine signal from thymic epithelial cells, Tα1 promotes T-cell maturation (CD4+CD8+ double-positive → single positive selection), TLR signalling sensitisation in peripheral immune cells, and IL-12-driven Th1 polarisation. Research applications: immunosenescence (aged thymic involution models, thymic output measurement by T-cell receptor excision circles TREC qPCR in peripheral blood), cancer immunotherapy adjuvant biology (checkpoint inhibitor combination in syngeneic tumour models), and viral infection immune recovery (post-viral immune reconstitution in sepsis, COVID-19, and viral challenge models).
Selecting Peptides for Endocrine Research: A Framework
The choice of research peptide for endocrine research depends on the specific axis, research question, and mechanistic hypothesis. GH axis research: CJC-1295 (sustained GHRH-R stimulation, metabolic), Sermorelin (pulsatile physiology, pituitary reserve), Ipamorelin (GHS-R1a, direct somatotroph + hypothalamic), Tesamorelin (clinical-analogue, lipodystrophy/MASH). HPA axis: Selank (stress-corticosterone-GR-FKBP5 biology), Semax (ACTH fragment without adrenocortical activity), DSIP (circadian-cortisol rhythm). HPG axis: Kisspeptin-10 (upstream GnRH driver), Follistatin (FSH regulation, ovarian biology), PT-141 (central melanocortin-reproductive), Oxytocin (social-neuroendocrine-HPG crosstalk). Pineal: Epitalon (AANAT-melatonin, circadian restoration). Incretin: Tirzepatide (GSIS, MASH, β-cell), Retatrutide (triple agonism, adiposity, liver). Thymic: Thymosin Alpha-1 (T-cell education, immunosenescence, cancer immunotherapy).
Key design principles for endocrine peptide research: (1) measure the axis biomarker before/after treatment to confirm target engagement (serum GH, IGF-1, LH, FSH, testosterone, cortisol, melatonin, insulin); (2) use appropriate positive controls (rhGH for GH axis, ACTH for HPA, GnRH for HPG, leuprolide for HPG suppression); (3) account for pulsatile hormone secretion by using serial sampling or AUC approaches rather than single-point measurements; and (4) distinguish direct pituitary effects from hypothalamic effects using selective stimulation tests and receptor antagonist controls. All research is conducted in Research Use Only frameworks.
🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified research peptides for endocrine and hormone axis research. View UK stock →
